Core Viewpoint - Powell Industries, Inc. has shown strong performance in the industrial products sector, particularly in electrical equipment and services, with a recent upgrade in stock rating reflecting positive market sentiment and growth potential [2][6]. Financial Performance - Powell reported earnings of $3.40 per share, exceeding the consensus estimate of $2.85 by $0.55, indicating strong profitability [4][6]. - The company achieved a return on equity of 31.63% and a net margin of 16.82%, showcasing effective management and operational efficiency [4][6]. - Revenue for the period was $251.18 million, which, while slightly below expectations, represented a 4.1% increase from the previous year [4]. Stock Performance - Following the earnings report, Powell's shares surged by 23.2%, reaching a high of $540 and last trading at $558.51, reflecting strong investor interest [3][6]. - The current stock price is $514, down 2.52% or $13.30 from the previous day, with fluctuations between $502.23 and $530 [5]. - Over the past year, the stock reached a high of $569.80 and a low of $146.02, with a current market capitalization of approximately $6.24 billion [5][6]. Analyst Ratings - Roth Capital upgraded Powell's stock to a "Buy" rating, increasing the price target from $450 to $585, indicating confidence in the company's future performance [2][6].

Core Insights - Snap-on Inc. reported strong fourth-quarter 2025 results, with both earnings and revenue exceeding expectations and showing year-over-year growth [1][9] Financial Performance - Earnings per share (EPS) reached $4.94, surpassing the Zacks Consensus Estimate of $4.86, and increased from $4.82 in the same quarter last year [1] - Net sales amounted to $1.232 billion, a 2.8% increase from the previous year, exceeding the Zacks Consensus Estimate of $1.218 billion [2] - Gross profit was $605.5 million, up 1.6% year over year, while gross margin contracted by 50 basis points to 49.2% [3] - Consolidated operating earnings, including financial services, were $339.6 million, reflecting a 2.3% year-over-year increase [4] Segment Analysis - The Commercial & Industrial Group's sales increased by 5% to $398.1 million, driven by favorable foreign currency translation and organic sales growth [5] - The Tools Group segment experienced a slight decline of 0.3% in sales to $505 million, attributed to lower activity in the U.S. market [6] - Sales in the Repair Systems & Information Group rose by 2.5% to $467.8 million, supported by increased activity with OEM dealerships [7] - Financial Services revenues grew by 7.5% year over year to $108 million, surpassing estimates [8] Financial Snapshot - As of the end of the third quarter of 2025, Snap-on had cash and cash equivalents of $1.62 billion and shareholders' equity of $5.93 billion [9] - The company anticipates capital expenditures of $100 million for 2026 [10] Future Outlook - Management expects resilience in 2026, focusing on core growth strategies and expansion into new markets and critical industries [11] - An effective tax rate of 22-23% is projected for 2026 [11]

Core Viewpoint - AngioDynamics reported a breakeven adjusted earnings per share for Q2 fiscal 2026, showing improvement from a loss in the previous year, but the stock has underperformed the S&P 500 recently, raising questions about its future performance leading up to the next earnings release [2][1]. Financial Performance - The company achieved pro-forma revenues of $79.4 million in Q2, an 8.8% increase year over year, surpassing the Zacks Consensus Estimate by 4.5% [4]. - U.S. net revenues were $67.6 million, reflecting a 7.8% year-over-year increase, exceeding the estimate of $62.3 million [5]. - Pro-forma international revenues reached $11.8 million, up 8.8% from the previous year, also surpassing projections [5]. Segment Analysis - The Med Tech segment reported pro-forma net sales of $35.7 million, a 13% increase year over year, exceeding the estimate of $32.7 million [6]. - Key drivers included Auryon sales of $16.3 million (up 18.6% year over year) and Mechanical Thrombectomy revenues of $11 million (up 3.9% year over year) [7]. - Pro-forma Med Device revenues totaled $43.8 million, a 5.6% increase from the prior year, also above projections [8]. Margin and Expenses - Pro-forma gross profit increased by 14% to $44.8 million, with gross margin expanding by 170 basis points to 56.4%, surpassing the projected margin of 54.2% [9]. - Sales and marketing expenses rose 4.4% to $26.7 million, while R&D expenses increased by 20.7% to $7.8 million [10]. Cash Position - At the end of Q2 fiscal 2026, AngioDynamics had cash and cash equivalents of $41.6 million, up from $38.8 million at the end of Q1, with no debt on the balance sheet [11]. Guidance and Outlook - The company updated its fiscal 2026 guidance, expecting net sales between $312 million and $314 million, an increase from previous guidance [12]. - Med Tech revenue growth is projected at 14-16%, while Med Device growth is expected to be flat to 1% [13]. - The adjusted loss per share is anticipated to be between 33 cents and 23 cents, with the consensus estimate at a loss of 28 cents [14]. - Estimates have trended downward recently, with a significant revision of -31.25% [15].

Core Viewpoint - Meta Platforms Inc. is experiencing a decline in stock price, attributed to broader market weaknesses, with a notable drop of 9.13% over the past five days [1]. Group 1: Stock Performance - Meta's stock was down 0.98% at $662.44 during Thursday's trading session [3]. - The Nasdaq-100 and S&P 500 indexes also saw declines of 1.32% and 1.04%, respectively [1]. Group 2: Earnings and Analyst Sentiment - The next earnings report is scheduled for April 29, 2026, with analysts noting a fading strength in earnings [2]. - The average price target for Meta's stock is $851.66, with a consensus rating of Buy [3]. Group 3: Financial Estimates and Valuation - The estimated EPS is $6.62, an increase from $6.43 year-over-year, while the revenue estimate is $55.41 billion, up from $42.31 billion year-over-year [4]. - The stock has a P/E ratio of 28.5x, indicating a premium valuation compared to peers [4]. Group 4: Analyst Ratings and Scores - Argus Research maintains a Buy rating with a target price of $800.00 [4]. - DA Davidson has raised its target to $850.00, and Morgan Stanley has raised its target to $825.00, both maintaining a Buy rating [4]. - The stock's value score is weak at 44.55, while the quality score is strong at 89.62, indicating a healthy balance sheet [4]. - Momentum is bearish with a score of 17.04, suggesting underperformance relative to the broader market [4].

Core Insights - Marathon Petroleum Corporation (MPC) reported fourth-quarter adjusted earnings per share of $4.07, significantly exceeding the Zacks Consensus Estimate of $2.73 and up from the year-ago adjusted profit of 77 cents, driven by strong performance in the Refining & Marketing segment and a 4.9% year-over-year decline in costs and expenses [1][2] Financial Performance - The company reported revenues of $33.4 billion, surpassing the Zacks Consensus Estimate of $29.6 billion, although this represented a slight decline of 0.1% year-over-year due to lower sales and reduced income from equity-method investments [2] - MPC distributed approximately $1.3 billion to shareholders in the fourth quarter and had $4.4 billion remaining under its share repurchase authorizations as of December 31, 2025 [3] Segment Analysis - The Refining & Marketing segment achieved an adjusted EBITDA of $2 billion, a 75.8% increase from the previous year's $1.1 billion, exceeding the consensus estimate by 26.7% [4] - The refining margin improved to $18.65 per barrel from $12.93 in the prior-year quarter, reflecting stronger crack spreads and beating the consensus estimate by 6.5% [5] - Refining capacity utilization was reported at 95%, up from 94% in the year-ago period [5] - The Midstream segment's adjusted EBITDA remained flat year-over-year at $1.7 billion, missing the consensus estimate by 3.7% due to higher operating costs and divestitures [7] Expense and Capital Expenditure - Total expenses for the fourth quarter were $30.7 billion, down from $32.3 billion in the previous year [8] - Capital expenditures for the quarter totaled $1.5 billion, with 31% allocated to Refining & Marketing and 67% to the Midstream segment [8] Future Guidance - MPC expects refining operating costs to average approximately $5.85 per barrel in the first quarter of 2026, with total refinery throughputs projected at about 2,740 thousand barrels per day [10] - Planned refining turnaround expenses for 2026 are expected to total approximately $1.35 billion, indicating a decline from 2025 levels [12] - The company anticipates that distributions from MPLX will fully fund MPC's dividends and standalone capital spending in 2026, with plans to return excess free cash flow to shareholders [15]

Core Viewpoint - Symbotic, Inc. reported mixed financial results for the first quarter, with earnings per share falling short of expectations while revenue exceeded estimates [2][3]. Financial Performance - Quarterly earnings were reported at $0.02 per share, missing the consensus estimate of $0.03 per share [2]. - Quarterly revenue reached $629.99 million, surpassing the Street estimate of $623.11 million [2]. Market Reaction - Following the earnings report, Symbotic's stock price increased by 13.12%, reaching $60.50 in extended trading [3]. Management Commentary - CEO Rick Cohen stated that the company is off to a strong start for the fiscal year, highlighting operational execution and product innovation as key drivers of economic benefits [2][3]. Future Outlook - Symbotic anticipates second-quarter revenue between $650 million and $670 million, exceeding the analyst estimate of $639.24 million [3].

Core Insights - Uber Technologies, Inc. reported fourth-quarter 2025 earnings that fell short of analyst expectations despite achieving double-digit revenue growth and record cash flow generation [1] - The company posted adjusted earnings per share of $0.71, missing the consensus estimate of $0.80 by 11% [1] - Revenue reached $14.4 billion, slightly above analyst expectations of $14.32 billion, marking a 20% year-over-year increase [1] Financial Performance - Quarterly trips increased by 22% to 3.8 billion, while gross bookings rose by 22% to $54.1 billion [2] - Uber generated record operating cash flow of $2.9 billion during the quarter and free cash flow of $2.8 billion, representing a 65% year-over-year increase [2] - Adjusted EBITDA rose by 35% to $2.5 billion, with margin improving to 4.6% of gross bookings from 4.2% a year earlier [2] Future Outlook - The company's first-quarter 2026 outlook disappointed investors, forecasting non-GAAP EPS of $0.65 to $0.72, below the consensus estimate of $0.75 [3] - Gross bookings are expected to range from $52.0 billion to $53.5 billion, representing constant-currency growth of 17% to 21% [3] - By segment, Mobility revenue rose by 19% year over year to $8.2 billion, Delivery revenue increased by 30% to $4.9 billion, and Freight revenue remained flat at $1.27 billion [3]

Core Insights - Boston Scientific Corporation reported fourth-quarter results that surpassed revenue and earnings expectations, but weakness in its electrophysiology business negatively impacted investor sentiment, leading to a more than 9% decline in shares during premarket trading [1] Financial Performance - The company reported fourth-quarter revenue of $5.29 billion, slightly above Stifel's estimate of $5.25 billion and the consensus forecast of $5.28 billion, with organic revenue growth for the quarter reaching 15.9% [1] - Earnings per share were reported at $0.80, exceeding Stifel's estimate of $0.77 and the consensus forecast of $0.78, attributed to a lower-than-expected effective tax rate of approximately 9.3% [3] Segment Performance - The electrophysiology segment, which represented roughly 17% of total quarterly revenue, underperformed expectations with segment revenue totaling $890 million, significantly below the consensus estimate of $933 million, primarily due to softer demand in the U.S. market [2] Future Guidance - For 2026, the company guided for organic revenue growth of 10% to 11% and earnings per share in the range of $3.43 to $3.49, with first-quarter organic revenue growth expected to range from 8.5% to 10%, indicating stronger growth anticipated in the latter half of the year [3]

Core Insights - Utah Medical Products, Inc. (UTMD) shares increased by 2% following the release of its fourth-quarter and full-year 2025 earnings, outperforming the S&P 500 index's 0.2% growth during the same period [1] - Over the past month, UTMD shares rose by 7.6%, significantly exceeding the S&P 500's 1.5% increase [1] Financial Performance - For Q4 2025, UTMD reported earnings per share (EPS) of 80.2 cents, a decrease of 6.3% from 85.7 cents in Q4 2024 [2] - Revenues for the quarter were $9 million, reflecting a 1.2% decline from $9.2 million in the same period a year ago [2] - Gross profit decreased by 1.1% to $5.26 million, down from $5.32 million in Q4 2024 [3] - Operating income fell 16.7% year over year to $2.4 million from $2.9 million, primarily due to increased operating expenses [3] - Net income was $2.6 million, an 11.6% decline from $2.9 million in the prior-year quarter [3] Key Business Metrics - Gross profit margin remained strong at 58.2%, nearly unchanged from 58.1% in the prior-year quarter [4] - Operating income margin declined to 27% from 32%, and net income margin fell to 28.4% from 31.7% [4] - Adjusted consolidated EBITDA for the quarter was $4 million, down 10% from $4.4 million a year ago, with EBITDA as a percentage of sales declining to 43.8% from 48.1% [4] Sales Performance - Domestic U.S. sales in Q4 declined 4.9% to $5.5 million from $5.7 million, with non-Filshie device sales accounting for most of the drop [5] - OEM sales decreased by 31.5% year over year, while Filshie device sales in the U.S. increased by 21.6% [5] - Outside the U.S. sales rose 4.9% to $3.6 million, largely due to favorable foreign exchange rates, but on a constant currency basis, OUS sales were up only 0.5% [5] Management Commentary - Management indicated that the fourth quarter provided a normalized comparison, with no sales to UTMD's China distributor in either Q4 2025 or Q4 2024, allowing margins to stabilize despite cost pressures [6] - Cost-of-living salary increases and raw material inflation continued to impact results, but effective cost containment helped prevent further deterioration [6] Operating Expenses - Operating expenses increased due to higher general and administrative (G&A) costs, including a $0.2 million charge related to an embezzlement case and a $0.4 million write-off tied to cancellation fees [7] - G&A expenses represented 23.2% of sales in Q4, up from 19.3% in the prior-year quarter [7] Factors Influencing Results - Revenue decline was primarily driven by softness in U.S. sales of non-Filshie medical devices and OEM components, with U.S. Filshie sales growth not sufficient to offset declines in other areas [8] - Favorable foreign exchange rates provided a modest benefit to reported international sales, particularly in Europe [8] Legal and Litigation Costs - Legal costs related to product liability litigation increased slightly to $0.4 million from $0.3 million the previous year, with 14 of 19 pending court cases dismissed by the end of January 2026 [9][10] Full-Year Performance - Full-year sales totaled $38.5 million, a 5.8% year-over-year decline from $40.9 million in 2024, with net income falling 18.7% to $11.3 million [11] - EPS dropped 12.1% year over year to $3.48, and gross margin declined to 57.1% from 59% in 2024 [11] Guidance and Future Outlook - Management expects sales to PendoTECH and the China distributor to remain at zero in 2026, aiming to offset losses with new product introductions and organic growth in Filshie sales [12] - There is substantial uncertainty regarding the recovery [12] Share Repurchase and Financial Position - During Q4 2025, UTMD repurchased 17,951 shares at an average cost of $55.35 per share, totaling $1 million [13] - The company ended the year with $85.8 million in cash and investments, up $2.8 million from the end of 2024, and no debt [14]

Core Insights - Atmos Energy (ATO) reported first-quarter fiscal 2026 earnings of $2.44 per share, exceeding the Zacks Consensus Estimate of $2.41 by 1.24% and showing a 9.42% increase from $2.23 in the same quarter last year [2][8] ATO's Revenues - The company generated revenues of $1.34 billion, falling short of the Zacks Consensus Estimate of $1.44 billion by 6.41%, but representing a 14.2% increase from $1.18 billion in the prior-year quarter [3] Highlights of ATO's Release - Operating income for the first fiscal quarter was $514.7 million, a 12% increase from $459.4 million in the year-ago quarter [4] - New rates worth $122.9 million were implemented, with an additional $81.2 million pending approval [4] - Net income reached $403 million, reflecting a 14.5% increase from $352 million in the year-ago quarter [4] ATO's Segmental Details - Distribution segment net income was $269.2 million, a 12% increase from $240.2 million in the year-ago quarter [5] - Pipeline and Storage segment income amounted to $134 million, a 19.6% increase from $112 million in the year-ago quarter [5] ATO's Financial Highlights - As of December 31, 2025, Atmos Energy reported $4.6 billion in available liquidity [6] - The company issued $600 million in 5.45% 30-year senior notes and settled $472 million through equity forward arrangements in the first quarter of fiscal 2026 [6] - Nearly $1 billion was invested in the first quarter, with 85% allocated for enhancing the safety and reliability of distribution and transportation systems [6] ATO's Guidance - Atmos Energy reaffirmed its fiscal 2026 earnings guidance at $8.15-$8.35 per share [7] - The anticipated capital expenditure for fiscal 2026 is $4.2 billion [7] - A quarterly dividend of $1 per common share was declared, indicating an annual dividend of $4, which is a 14.9% increase from fiscal 2025 [7]